US 11,926,643 B2
Heterocyclic GLP-1 agonists
Qinghua Meng, Shanghai (CN); Xichen Lin, Shanghai (CN); Haizhen Zhang, Shanghai (CN); Weiqiang Xing, Shanghai (CN); Hui Lei, Shanghai (CN); and Andrew Jennings, San Francisco, CA (US)
Assigned to Gasherbrum Bio, Inc., South San Francisco, CA (US)
Filed by Gasherbrum Bio, Inc., South San Francisco, CA (US)
Filed on Jun. 29, 2022, as Appl. No. 17/853,755.
Application 17/853,755 is a continuation of application No. 17/571,351, filed on Jan. 7, 2022, granted, now 11,492,365.
Application 17/571,351 is a continuation of application No. PCT/CN2021/075488, filed on Feb. 5, 2021.
Claims priority of application No. PCT/CN2020/074537 (WO), filed on Feb. 7, 2020; and application No. PCT/CN2020/109304 (WO), filed on Aug. 14, 2020.
Prior Publication US 2023/0174565 A1, Jun. 8, 2023
Int. Cl. C07F 9/6561 (2006.01)
CPC C07F 9/6561 (2013.01) 20 Claims
 
1. A method of treating type 2 diabetes mellitus in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound selected from:
 
 

OG Complex Work Unit Chemistry
 121a
 
 

OG Complex Work Unit Chemistry
 144a
 
 

OG Complex Work Unit Chemistry
 145a
 
 

OG Complex Work Unit Chemistry
 146a
 
and
 
 
 

OG Complex Work Unit Chemistry
 146b
 
or a pharmaceutically acceptable salt thereof.